BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Press Releases

  Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

  May 12, 2026

   · 

  11 min read
• Press Releases

  BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

  May 12, 2026

   · 

  9 min read
• Press Releases

  Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

  May 12, 2026

   · 

  5 min read
• Press Releases

  Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

  May 12, 2026

   · 

  15 min read
• Press Releases

  Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

  May 12, 2026

   · 

  6 min read
• Press Releases

  GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class

  May 12, 2026

   · 

  4 min read
• Press Releases

  CardioPharma Reviews Applications to Explore Non-Cardiovascular Benefits of CVD Polypill

  May 12, 2026

   · 

  4 min read
• Press Releases

  Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

  Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein

  May 12, 2026

   · 

  5 min read
• Press Releases

  DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence

  Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid Analgesics Late-Breaking Results to be Presented at CPDD 2026 Annual Meeting

  May 12, 2026

   · 

  5 min read
• Press Releases

  Zenith Capital Corp. Amends Promissory Notes

  May 12, 2026

   · 

  6 min read